Physician profile
David B Jameson
NPI 1083616502
$1,336.35
in general payments reported to CMS, 2019-2025
18 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $168 · 2021: $191 · 2022: $228 · 2023: $169 · 2024: $157 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $450.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $266.54 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $239.98 | 2019-2025 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.76 | 2020-2025 | Jardiance |
| Lilly USA, LLC | $178.27 | 2019-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $99.28 | 2019-2023 | |
| Amgen INC. | $51.27 | 2019-2024 | Evenity, Prolia |
| Organogenesis INC. | $41.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $39.59 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $38.06 | 2020-2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $28.37 | 2019 | |
| Merck Sharp & Dohme LLC | $26.63 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $26.60 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $25.02 | 2021-2022 | |
| Seqirus USA INC | $19.96 | 2025 | Flucelvax, Fluad |
| Teva Pharmaceuticals USA, INC. | $18.33 | 2023 | Austedo Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $17.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.85 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jameson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.